Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. The company is headquartered in Woburn, Massachusetts.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $1.52M |
| EBITDA | $-9.30M |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -229.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-6.04 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 632.00% |
| Shares Outstanding | 0 |
| Float | $1.73M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |